1°) Criblage pharmacologique ex vivo de chimio sensibilité dans le cancer thyroïdien réfractaire et métastatique
Dossier d’Angers, porteur : V. Suteau
Financement Bourse = IPSEN-GTE-TUTHYREF – 10 000 euros
2°) Precision medicine in prediction of radioiodine response and refractoriness: pediatric and adolescent differentiated thyroid cancer as an model to understand refractory DTC (DTCped)
Dossier de Villejuif, porteur : L. Lamartina
Financement Bourse = IPSEN-GTE-TUTHYREF – 10 000 euros
3°) ASTEROID (ASsessment of TROP2 Expression in Refractory thyroid cancers and anaplastic thyrOID cancers)
Dossier de Caen, porteur : R. Ciappuccini
Financement Bourse = EISAI-GTE-TUTHYREF – 20 000 euros
